Clinical Trial Update: Lidocaine Supplement for Minimal Invasive Parathyroid Surgery [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating lidocaine as a supplement for minimally invasive parathyroid surgery has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parathyroid Disease

Drugs mentioned

• Lidocaine (Xylocaine) (Lidocaine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Parathyroid Disease | Phase 3 | Status: WITHDRAWN